{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:36:50Z","timestamp":1777383410027,"version":"3.51.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,4]],"date-time":"2021-12-04T00:00:00Z","timestamp":1638576000000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012401","name":"Beijing Science and Technology Planning Project","doi-asserted-by":"publisher","award":["Z171100001017182"],"award-info":[{"award-number":["Z171100001017182"]}],"id":[{"id":"10.13039\/501100012401","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2018zx10301-404"],"award-info":[{"award-number":["2018zx10301-404"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To establish a prediction of HBsAg seroconversion in children with chronic hepatitis B (CHB), so as to help clinicians to choose therapeutic strategy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 63 children with HBeAg-positive CHB aged 1 to 17\u00a0years, who admitted to the fifth medical center of Chinese PLA general hospital and treated with interferon \u03b1 (IFN\u03b1) 48\u00a0weeks were enrolled, the clinical data were measured. Based on the results of HBsAg seroconversion (HBsAg\u2009&lt;\u20090.05\u00a0IU\/mL and anti-HBsAg\u2009&gt;\u200910\u00a0IU\/L) at week 48, the patients were divided into HBsAg seroconversion (S) group and non-HBsAg seroconversion (NS) group. Multivariate COX regression was used to identify the impact factors associated with HBsAg seroconversion. A novel prediction index was established and the area under the receiver operating characteristic curve (AUROC) was used to assess the prediction for HBsAg seroconversion.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The 63 patients were divided into S group (20.6%, 13\/63) and NS group (79.4%, 50\/63). Univariate and multivariate analysis identified age, baseline intrahepatic cccDNA and serum HBsAg levels were independent impact factors for HBsAg seroconversion. Intrahepatic cccDNA was positively correlated with serum HBsAg (r\u2009=\u20090.464, <jats:italic>p<\/jats:italic>\u2009=\u20090.000). AUROC of HBV cccDNA was 0.83 (95% CI 0.71 to 0.95) and AUROC of baseline HBsAg was 0.77 (95% CI 0.61 to 0.92). Intrahepatic cccDNA\u2009\u2264\u20090.08 log<jats:sub>10<\/jats:sub> copies\/10<jats:sup>6<\/jats:sup> cell is regarded as cutoff value, the positive predictive value(PPV) and negative predictive value(NPV) for HBsAg seroconversion were 86.8% and 60.0%, respectively, with a sensitivity of 92.0% and specificity of 56.2%. HBsAg\u2009\u2264\u20093.68 log<jats:sub>10<\/jats:sub> IU\/mL is used as cut off value, the PPV and NPV for HBsAg seroconversion were 91.2% and 56.3%, respectively; the sensitivity and specificity was 86.0% of 69.2%, respectively. There was no statistical difference between them for predicting HBsAg seroconversion (<jats:italic>p<\/jats:italic>\u2009=\u20090.146).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>HBsAg seroconversion can be predicted by the baseline serum HBsAg or intrahepatic cccDNA in children with CHB. Using the index, clinicians can choose more reasonable therapeutic strategy and reduce the waste of medical resources.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-021-06883-1","type":"journal-article","created":{"date-parts":[[2021,12,4]],"date-time":"2021-12-04T17:02:42Z","timestamp":1638637362000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Prediction for HBsAg seroconversion in children with chronic hepatitis B"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9326-3066","authenticated-orcid":false,"given":"Yan-Wei","family":"Zhong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Min","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ce","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiao-Jiao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Jie","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-He","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiu-Chang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,4]]},"reference":[{"issue":"1","key":"6883_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/hep.30231","volume":"69","author":"G Ligat","year":"2019","unstructured":"Ligat G, Schuster C, Baumert TF. Hepatitis B virus core variants, liver fibrosis, and hepatocellular carcinoma. Hepatology. 2019;69(1):5\u20138.","journal-title":"Hepatology"},{"issue":"6","key":"6883_CR2","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.jhep.2018.08.012","volume":"69","author":"C Ko","year":"2018","unstructured":"Ko C, Chakraborty A, Chou WM, Hasreiter J, Wettengel JM, Stadler D, et al. Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels. J Hepatol. 2018;69(6):1231\u201341.","journal-title":"J Hepatol"},{"key":"6883_CR3","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1136\/gutjnl-2016-312162","volume":"67","author":"L Allweiss","year":"2018","unstructured":"Allweiss L, Volz T, Giersch K, Kah J, Raffa G, Petersen J, et al. Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo. Gut. 2018;67:542\u201352.","journal-title":"Gut"},{"key":"6883_CR4","doi-asserted-by":"publisher","first-page":"4644","DOI":"10.3748\/wjg.v21.i15.4644","volume":"21","author":"S Bowden","year":"2015","unstructured":"Bowden S, Locarnini S, Chang TT, Chao YC, Han KH, Gish R, et al. Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine. World J Gastroenterol. 2015;21:4644\u201351.","journal-title":"World J Gastroenterol"},{"key":"6883_CR5","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/jmv.24601","volume":"89","author":"N Chuaypen","year":"2017","unstructured":"Chuaypen N, Sriprapun M, Praianantathavorn K, Payungporn S, Wisedopas N, Poovorawan Y, et al. Kinetics of serum HBsAg and intrahepatic cccDNA during pegylated interferon therapy in patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. J Med Virol. 2017;89:130\u20138.","journal-title":"J Med Virol"},{"key":"6883_CR6","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.3892\/mmr.2014.1972","volume":"9","author":"P Ruan","year":"2014","unstructured":"Ruan P, Zhou B, Dai X, Sun Z, Guo X, Huang J, et al. Predictive value of intrahepatic hepatitis B virus covalently closed circular DNA and total DNA in patients with acute hepatitis B and patients with chronic hepatitis B receiving anti-viral treatment. Mol Med Rep. 2014;9:1135\u201341.","journal-title":"Mol Med Rep"},{"issue":"10","key":"6883_CR7","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1111\/j.1440-1746.2011.06766.x","volume":"26","author":"B Takkenberg","year":"2011","unstructured":"Takkenberg B, Terpstra V, Zaaijer H, Weegink C, Dijkgraaf M, Jansen P, et al. Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir. J Gastroenterol Hepatol. 2011;26(10):1527\u201335.","journal-title":"J Gastroenterol Hepatol"},{"key":"6883_CR8","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","volume":"57","author":"European Association for the Study of the Liver","year":"2012","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167\u201385.","journal-title":"J Hepatol"},{"key":"6883_CR9","unstructured":"Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association, Hou JL, lai W. [The guideline of prevention and treatment for chronic hepatitis B: a 2015 update]. Zhonghua Gan Zang Bing Za Zhi. 2015;23(12):888\u2013905."},{"key":"6883_CR10","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1016\/j.cca.2011.06.031","volume":"412","author":"Y Zhong","year":"2011","unstructured":"Zhong Y, Han J, Zou Z, Liu S, Tang B, Ren X, et al. Quantitation of HBV covalently closed circular DNA in micro formalin fixed paraffin-embedded liver tissue using rolling circle amplification in combination with real-time PCR. Clin Chim Acta. 2011;412:1905\u201311.","journal-title":"Clin Chim Acta"},{"key":"6883_CR11","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/1471-2334-11-262","volume":"11","author":"YW Zhong","year":"2011","unstructured":"Zhong YW, Li J, Song HB, Duan ZP, Dong Y, Xing XY, et al. Virologic and clinical characteristics of HBV genotypes\/subgenotypes in 487 Chinese pediatric patients with CHB. BMC Infect Dis. 2011;11:262.","journal-title":"BMC Infect Dis"},{"key":"6883_CR12","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/1471-2334-9-149","volume":"9","author":"PA Tonetto","year":"2009","unstructured":"Tonetto PA, Gon\u00e7ales NS, Fais VC, Vigani AG, Gon\u00e7ales ES, Feltrin A, et al. Hepatitis B virus: molecular genotypes and HBeAg serological status among HBV-infected patients in the southeast of Brazil. BMC Infect Dis. 2009;9:149.","journal-title":"BMC Infect Dis"},{"issue":"9","key":"6883_CR13","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1007\/s11655-020-3426-7","volume":"26","author":"JB Wang","year":"2020","unstructured":"Wang JB, Wang ZX, Jing J, Zhao P, Dong JH, Zhou YF, et al. Exploring an integrative therapy for treating COVID-19: a randomized controlled trial. Chin J Integr Med. 2020;26(9):648\u201355.","journal-title":"Chin J Integr Med"},{"issue":"6","key":"6883_CR14","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1111\/apa.14626","volume":"108","author":"ME El-Raziky","year":"2019","unstructured":"El-Raziky ME, Fouad HM, Abd Elkhalak NS, Ghobrial CM, El-Karaksy HM. Paediatric chronic hepatitis B virus infection: are children too tolerant to treat? Acta Paediatr. 2019;108(6):1144\u201350.","journal-title":"Acta Paediatr"},{"issue":"5","key":"6883_CR15","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.jhep.2019.06.009","volume":"71","author":"S Zhu","year":"2019","unstructured":"Zhu S, Dong Y, Wang L, Liu W, Zhao P. Early initiation of antiviral therapy contributes to a rapid and significant loss of serum HBsAg in infantile-onset hepatitis B. J Hepatol. 2019;71(5):871\u20135.","journal-title":"J Hepatol"},{"key":"6883_CR16","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.3851\/IMP1696","volume":"15","author":"TH Su","year":"2010","unstructured":"Su TH, Hsu CS, Chen CL, Liu CH, Huang YW, Tseng TC, et al. Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B. Antivir Ther. 2010;15:1133\u20139.","journal-title":"Antivir Ther"},{"key":"6883_CR17","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","volume":"63","author":"GA Kim","year":"2014","unstructured":"Kim GA, Lim YS, An J, Lee D, Shim JH, Kim KM, et al. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut. 2014;63:1325\u201332.","journal-title":"Gut"},{"key":"6883_CR18","doi-asserted-by":"publisher","first-page":"895","DOI":"10.3851\/IMP2580","volume":"18","author":"RB Takkenberg","year":"2013","unstructured":"Takkenberg RB, Jansen L, de Niet A, Zaaijer HL, Weegink CJ, Terpstra V, et al. Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-\u03b12a and adefovir. Antivir Ther. 2013;18:895\u2013904.","journal-title":"Antivir Ther"},{"key":"6883_CR19","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.clim.2006.09.006","volume":"122","author":"Z Zhang","year":"2007","unstructured":"Zhang Z, Chen D, Yao J, Zhang H, Jin L, Shi M, et al. Increased infiltration of intrahepatic DC subsets closely correlate with viral control and liver injury in immune active pediatric patients with chronic hepatitis B. Clin Immunol. 2007;122:173\u201380.","journal-title":"Clin Immunol"},{"key":"6883_CR20","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/liv.12403","volume":"34","author":"M Martinot-Peignoux","year":"2014","unstructured":"Martinot-Peignoux M, Lapalus M, Asselah T, Marcellin P. HBsAg quantification: useful for monitoring natural history and treatment outcome. Liver Int. 2014;34:97\u2013107.","journal-title":"Liver Int"},{"key":"6883_CR21","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.jhep.2016.08.009","volume":"66","author":"M Cornberg","year":"2017","unstructured":"Cornberg M, Wong VW, Locarnini S, Brunetto M, Janssen HLA, Chan HL. The role of quantitative hepatitis B surface antigen revisited. J Hepatol. 2017;66:398\u2013411.","journal-title":"J Hepatol"},{"issue":"3","key":"6883_CR22","first-page":"177","volume":"30","author":"MH Li","year":"2017","unstructured":"Li MH, Zhang L, Qu XJ, Lu Y, Shen G, Li ZZ, et al. The predictive value of baseline HBsAg level and early response for HBsAg loss in patients with HBeAg-positive chronic hepatitis B during pegylated interferon alpha-2a treatment. Biomed Environ Sci. 2017;30(3):177\u201384.","journal-title":"Biomed Environ Sci"},{"key":"6883_CR23","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1128\/JCM.00760-17","volume":"55","author":"Y Gao","year":"2017","unstructured":"Gao Y, Li Y, Meng Q, Zhang Z, Zhao P, Shang Q, et al. Serum hepatitis B virus DNA, RNA, and HBsAg: which correlated better with intrahepatic covalently closed circular DNA before and after nucleos(t)ide analogue treatment? J Clin Microbiol. 2017;55:2972\u201382.","journal-title":"J Clin Microbiol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06883-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-021-06883-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06883-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,4]],"date-time":"2021-12-04T17:04:57Z","timestamp":1638637497000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-06883-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6883"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-06883-1","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"2 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the 5th Medical Center of Chinese PLA General Hospital Research Ethnics Committee, and written informed consents for therapy and study were obtained from each patient\u2019s parents.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1211"}}